University of Pittsburgh researchers have developed an innovative approach to enhance the effectiveness of adoptive cell therapy for cancer treatment by redirecting glucose metabolism. This method addresses the metabolic stresses that T cells endure during in vitro expansion, which can limit their persistence and function in vivo. By using the drug dichloroacetate, an inhibitor of pyruvate dehydrogenase kinase, the researchers promote mitochondrial health, resulting in more robust antitumor responses. This technology has demonstrated compelling results in both mouse models and human cell cultures, offering a promising pathway to improve the therapeutic outcomes of T cell-based cancer therapies.
Description
The genetic modification and subsequent in vitro expansion of these T cells can lead to significant metabolic stress, reducing their efficacy once reintroduced into the patient. This technology proposes a novel method of redirecting glucose metabolism within the T cells, rather than inhibiting it, to enhance their function and longevity. The use of dichloroacetate to inhibit pyruvate dehydrogenase kinase shifts the metabolic balance towards improved mitochondrial function, which is crucial for the energy demands of active T cells. This redirection strategy maintains cell viability and boosts the antitumor activity of T cells, potentially transforming the landscape of adoptive cell therapy.
Applications
- Cancer Immunotherapy
- Cellular Therapy
- Metabolic Research
Advantages
This method offers a significant improvement over existing strategies by focusing on the redirection rather than inhibition of glucose metabolism, thereby avoiding the adverse effects associated with traditional approaches. The ability to enhance mitochondrial health during T cell expansion leads to greater cell viability, improved antitumor responses, and a more effective overall therapy. This innovation not only supports the development of more potent cancer therapies but also opens the door to novel pharmaceutical interventions aimed at optimizing cell metabolism for therapeutic purposes.
Invention Readiness
The technology has been validated through extensive in vivo and in vitro studies, including in immunocompetent solid tumor mouse models, healthy human T cells, human tumor-infiltrating lymphocytes (TIL) cultures, and human CAR-T cell therapy in xenograft models. The technology is at an advanced stage of development and is poised for further optimization and commercialization.
IP Status
https://patents.google.com/patent/US20230381312A1
